and Tc-TMHEA displays selective tumor uptake, suggesting it is a potential tumor imaging agent.
Introduction
In clinical oncology, 2′-deoxy-2′-[ F-FDG is a non-specific tracer for tumor imaging since glucose is highly utilized by many other cells, such as macrophages found in inflammatory lesions [1, 2] . To overcome this inconvenience of thymidine ( 18 F-FLT) [1, [3] [4] [5] and its analog 18 F-FMAU [8] have demonstrated their good imaging features. However, these tracers were labeled with either 11 C or 18 F, which are short half-life isotopes produced by a cyclotron, with complicated radiochemical synthesis and the lower radiochemical yield and high cost of PET examination, all of which limit their use as tracers in routine clinical studies.
Technetium-99m ( 99m Tc), the most commonly used radioisotope in SPECT, is continuously available at a reasonable cost in many hospitals and has ideal nuclear properties for imaging (T 1/2 = 6.02 h, γ = 140 keV). Therefore it is important to develop a 99m Tc labeled thymidine analog so as to provide the ideal characteristics needed for routine clinical studies [9] [10] [11] . In the previous work of our group, a series of technetium-99m labeled thymine derivatives have been prepared and their in vivo biological properties were systematically investigated [12, 13] . It was found that the uptake ratio of tumor to muscle of 99m Tc-NHT was higher than that of 99m Tc-ANMdU, which means that uptake ratio of tumor to muscle maybe increase with increasing carbon chain length between the thymidine and N 2 S 2 ligand. However, to the best of our knowledge, extension and optimization of the linker chain between the thymidine and N 2 S 2 ligand to develop novel tumor imaging agent has been largely unexplored.
For the purpose of developing novel tumor imaging agents with excellent biological properties, we have continued to extend the number of methylene units between the thymidine and N 2 S 2 ligand. In this work, two novel 99m Tc-labeled thymidine derivatives were prepared and reported, i.e., 
Results and Discussion

Chemistry and Radiolabeling
TMHEA and TMHHA were synthesized by seven step reactions from the starting materials ethanediamine and hexanediamine, respectively. The target compounds were identified by MS, 1 H-NMR and 13 C-NMR, and the results agreed well with the expected chemical structures. According to the TLC and HPLC analysis, the radiochemical purities of 99m Tc-TMHEA and   99m Tc-TMHHA were all greater than 95%. The radiolabeled compounds were used immediately after the formulation for both in vitro and in vivo studies.
In Vitro Stability and Octanol-Water Partition Coefficient
The in vitro stabilities of   99m   Tc-TMHEA and   99m Tc-TMHHA were performed in PBS (pH = 7.4) for different time intervals (1, 2, 3, 4, 5, 6 h) at 37 °C. The stability was presented as RCP on the basis of the HPLC analysis. After 6 h of incubation, more than 95% of 99m Tc-TMHEA and   99m Tc-TMHHA remained intact in the PBS. The results indicate that the labeling efficiency of these complexes was high and their stability duration was long enough to allow further biodistribution and imaging studies.
The octanol-water partition coefficients (logP) for 99m   Tc-TMHEA and   99m Tc-TMHHA were 1.01, 0.99 and 1.06, 1.02 in PBS at two different pH values of 7.0 and 7.4, respectively (see Table 1 ), which demonstrated that the longer the carbon chain, the smaller the logP, and the liposolubility at pH = 7.4 was higher than that at pH = 7.0. As well known, the logP value is a very useful parameter that can be used to understand the behavior of a drug and predict its distribution in the organism in combination with other parameters [14] . 
Blood Kinetics Studies
Pharmacokinetic parameters are listed in Table 2 . Figure 3 shows the blood clearance of Tc-TMHHA, respectively. In the early phase, the blood clearance of 99m Tc-TMHHA was slower than 99m Tc-TMHEA. After 2 h, the radioactivity concentration of two tracer agents in blood reaches an equilibrium which coincides with the pharmacokinetic parameters CL, AUC and the pharmacokinetic curves. Tc-TMHHA were determined in tumor-bearing mice, and the data is shown in Table 3 Tc-TMHHA are mainly through the renal pathway, and to a lesser extent, through the hepatobiliary pathway.
At 5 min post injection, the tumor uptake was 2.51 ± 0.28 and 2.38 ± 0.41 %ID/g, the muscle uptake was 1.93 ± 0.16 and 1.75 ± 0.21 %ID/g for 99m Tc-TMHEA and 99m Tc-TMHHA, respectively. The tumor uptake value was higher than that of muscle, and the uptake ratio of tumor to muscle was increased with time for Tc-TMHHA, respectively. In previous work of our group [12, 13] , it was found that the uptake ratio of tumor to muscle increases with the increasing carbon chain length between the thymidine and N 2 S 2 ligand (i.e., from Tc-TMHEA (see Table 3 ), and the both ratios of Tc-NHT (4.41 ± 0.32, at 2 h post injection) [13] . This indicates that limitless extension of the carbon chain is not always beneficial to improve the uptake ratio of tumor to muscle. The uptake ratio of tumor to bone of 99m Tc-TMHHA was decreased with time. The uptake ratio of tumor to blood was increased with time for Tc-TMHHA had similar biological behavior, however, the uptake ratios of tumor to muscle, tumor to bone and tumor to blood of Tc-NHT, which suggests that limitless extension of the carbon chain is not always beneficial to improve the uptake ratios of tumor to muscle, tumor to bone and tumor to blood. 
Abnormal Toxicity Test
The abnormal toxicity test was evaluated by the death and 48-h survival of the mice, which were injected with 0. 2 mL   99m   Tc-TMHEA and   99m Tc-TMHHA (3.7 MBq), respectively. Saline-injected (of the same volume) mouse group was used as the control group. As expected, the mice showed no signs of toxicity through the overall study period.
Experimental
General
All analytical chemical reagents employed were purchased from commercial sources and used without further purification. Na 99m TcO 4 was supplied by Jiangsu Institute of Nuclear Medicine. Electron spray ion (ESI) mass spectra were measured using a Waters Platform ZMD4000 LC/MS. NMR spectra were obtained on a Bruker DRX-500 spectrometer, and the chemical shift value was given relative to the internal tetramethylsilane (TMS). A Packard multi-prias γ Counter was used. The animal experiments in this study were approved by the Animal Care and Ethnics Committee of Jiangsu Institute of Nuclear Medicine.
Synthesis of 99m
Tc-TMHEA and Tc-TMHHA were synthesized according to the synthetic route summarized in Scheme 1.
General Procedure for the Preparation of Compounds 1a and 1b
The solution of corresponding diamine (0.5 mol) in methanol (200 mL) was cooled down to 0 °C and t-butoxycarbonyl anhydride (t-BOC 2 O, 10.8 g, 50 mmol) in methanol (10 mL) was added dropwise. The reaction mixture was stirred for 20 h at room temperature. The reaction mixture was concentrated and diluted with water. The mixture was then extracted with CH 2 Cl 2 (60 mL) for three times. The organic layer was dried with anhydrous Na 2 SO 4 and the solvent was evaporated to give compound 1. 
N-BOC-ethanediamine
6 mmol) were dissolved in an acetone/DMF (1/1, v/v) mixed solvent (100 mL), and the mixture was heated at 80 °C and stirred for 20 h under nitrogen atmosphere. Then the solvent was evaporated under reduced pressure and the desired product (compound 2) was purified by silica gel column chromatography using ethyl acetate/methanol = 4/1 (v/v). 
N-BOC-N′-{N′′-[2-(2-(S-(4-Methoxybenzyl)sulfanyl)ethylamino)acetyl]-S-(4-methoxybenzyl)-2-
General Procedure for the Preparation of Compounds 3a and 3b
A mixture of compound 2 (1.5 mmol) and potassium carbonate in acetone (30 mL), and iodomethane (95 μL, 1.5 mmol) in acetone (20 mL) was added. The reaction mixture was stirred for 2 h, then the solvent was evaporated under reduced pressure. The desired product (compound 3) was purified by silica gel column chromatography using ethyl acetate/methanol/triethylamine = 19/2/1 (v/v). 
N-BOC-N′-Methyl-N′-{N′′-[2-(2-(S-(4-methoxybenzyl)sulfanyl)ethylamino)acetyl]-S-(4methoxybenzyl)-2-aminoethylsulfanyl-1-hexanamide}-ethanediamine
N-BOC-N′-Methyl-N′-{N′′-[2-(2-(S-(4-methoxybenzyl)sulfanyl)ethylamino)acetyl]-S-(4-methoxybenzyl)-2-aminoethylsulfanyl-1-hexanamide}-hexamethylenediamine
General Procedure for the Preparation of Compounds 4a and 4b
The solution of compound 3 (1.3 mmol) in methanol (50 mL), and concentrated hydrochloric acid (5 mL) was added. The reaction mixture was stirred for 4 h at 45 °C, then the solvent was evaporated under reduced pressure. The residue was dissolved in water (30 mL) and the mixture was adjusted to pH 10 by aqueous sodium hydroxide solution (2 mol/L). The mixture was then extracted with ethyl acetate (30 mL) for three times. The organic layer was dried with anhydrous Na 2 SO 4 and the solvent was evaporated under reduced pressure. The desired product (compound 4) was purified by silica gel column chromatography using ethyl acetate/methanol/triethylamine = 8/8/1 (v/v). 
N-Methyl-N-{N′-[2-(2-(S-(4-methoxybenzyl)sulfanyl)ethylamino)acetyl]-S-(4-methoxybenzyl)-2-aminoethylsulfany-1-hexanamide}-ethanediamine
N-Methyl-N-{N′-[2-(2-(S-(4-methoxybenzyl)sulfanyl)ethylamino)acetyl]-S-(4-methoxybenzyl)-2-aminoethylsulfanyl-1-hexanamide}-hexamethylenediamine
General Procedure for the preparation of compounds 5a and 5b
The solution of compound 4 (0.96 mmol) and triethylamine (2 mL) in CH 2 Cl 2 (80 mL) was cooled down to 0 °C and 3′,5′-diacetyl-5-bromo-N-BOC-thymidine (0.44 g, 0.86 mmol) in CH 2 Cl 2 (20 mL) was added. The reaction mixture was stirred for 4 h at room temperature. The mixture was washed with aqueous NaHCO 3 (75 mL × 2) and H 2 O (50 mL), respectively. The organic layer was dried with anhydrous Na 2 SO 4 and the solvent was evaporated. The residue was purified by column chromatography using ethyl acetate/ methanol/triethylamine (19/1/1, v/v) to give compound 5. 78 (s, 6H), 3.60-3.71 (m, 4H), 3.55 (s, 2H), 3.30-3.50 (m, 4H), 2.65-2.70 (s, 2H) 88 (m, 6H), 1.60 (s, 9H), 1.39-1.48 (m, 8H), 1.26-1.30 (m, 6H) ; 13 C-NMR (CDCl 3 ): δ (ppm) 171.4, 170.8, 170.3, 170.2, 170.1, 162.3, 159.1, 154.3, 149.7, 136.5, 130.0, 129.8,  129.8, 129.7, 129.3, 114.3, 114.2, 114.1, 109.9, 84.9, 83.3, 78.8, 74.4 
N-(3′,5′-Diacetyl-N′-BOC-thymidinyl)-N′′-methyl-N′′-{N′′′-[2-(2-(S-(4-methoxybenzyl)sulfanyl)ethyl amino) acetyl]-S-(4-methoxybenzyl)-2-aminoethylsulfanyl-1-hexanamide}-ethanediamine
N-(3′,5′-Diacetyl-N′-BOC-thymidinyl)-N′′-methyl-N′′-{N′′′-[2-(2-(S-(4-methoxybenzyl)sulfanyl)ethyl amino) acetyl]-S-(4-methoxybenzyl)-2-aminoethylsulfanyl-1-hexanamide}-hexamethylenediamine
General Procedure for the Preparation of Compounds 6a and 6b
The mixture of compound 5 (0.45 mmol) and potassium carbonate (1 g, 7.25 mmol) in methanol (50 mL) was heated to reflux for 4 h. Then the solvent was evaporated under reduced pressure and the residue was dissolved in chloroform (50 mL). The organic layer was washed with H 2 O (50 mL) and dried with anhydrous Na 2 SO 4 . The compound 6 was purified by silica gel column chromatography using chloroform /methanol/triethylamine (5/2/0.1, v/v). 
N-Thymidinyl-N′-methyl-N′-{N′′-[2-(2-(S-(4-methoxybenzyl)sulfanyl)ethylamino)acetyl]-S-(4-methoxybenzyl)-2-aminoethylsulfanyl-1-hexanamide}-ethanediamine
N-Thymidinyl-N′-methyl-N′-{N′′-[2-(2-(S-(4-methoxybenzyl)sulfanyl)ethylamino)acetyl]-S-(4-methoxybenzyl)-2-aminoethylsulfanyl-1-hexanamide}-hexamethylenediamine
General Procedure for the Preparation of Compounds 7a and 7b
Compound 6 (0.17 mmol) was dissolved in trifluoroacetic acid (5 mL) and cooled in ice bath to 0 °C. Anisole (0.26 mL) and Hg(AcO) 2 (0.17 g, 0.53 mmol) were added. The reaction mixture was stirred for 30 min at room temperature and then concentrated in vacuum to obtain viscous brown oil that was dried in vacuum for 30 min. Dry diethyl ether (15 mL) was added to the oil and the resultant suspension stirred for about 10min. The ether was decanted and the precipitate washed again with another 15 mL of ether. The colorless solid was collected by suction filtration, dried in vacuum and dissolved again in absolute ethanol (10 mL). H 2 S gas was passed through the solution for 20 min. The reaction mixture was filtered and the filtrate concentrated under vacuum to afford compound 7 as a colorless oil. A solution of compound 7 (50 μL, 2 mg of compound 7 dissolved in 2 mL ethanol) was added to a mixture of sodium glucoheptonate (0.8 mL, 10 mg/mL), freshly prepared solution of stannous chloride dehydrate (20 μL, 1.0 mg SnCl 2 .2H 2 O dissolved in 1 mL 0.1 mol/L hydrochloric acid solution), and pertechnetate eluate (50 μL, 37 MBq). The reaction mixture was vortexed adequately and reacted at 100 °C for 30 min. Tc-colloidal impurities remain at the bottom on polyamide layer strip, while 8a and 8b both migrate with the solvent front. The strips were cut into pieces of 1 cm and the activity of these pieces was counted to determine the RCP value on a well-type γ counter.
N-Thymidinyl-N′-methyl-N′-{N′′-[2-sulfanylethylamino)acetyl]-
Quality Control of
HPLC
The RCP of Tc-TMHHA were determined by HPLC using a Waters 600-type instrument. The sample was carefully passed through a Millipore filter and injected into the HPLC column (SunFire TM C18, PN: 186002559, 4.6 mm × 150 mm × 5 μm, Waters, Milford, MA, USA). Radioanalysis of the labeled compound was conducted using a Cd (Te) detector. The flow rate was adjusted to 1.0 mL/min and the isocratic mobile phase was 68% water and 32% methanol. Tc-TMHHA (20 μL, 0.74 MBq) was added to the two-phase system of 3.0 mL n-octanol and 3.0 mL PBS, respectively. The mixture was vortexed for 1 min × 3 and centrifuged for 5 min at 4,000 r/min to ensure complete separation of layers, and then 1.0 mL n-octanol and 1.0 mL PBS were taken out and counted with a γ-counter. Afterwards, 1.0 mL n-octanol was transferred to another tube containing 3.0 mL PBS and 2.0 mL n-octanol. The above procedure was repeated for six times. LogP values were calculated using the formula of logP = log[counts(n-octanol)/counts(PBS)]．
Tumor Models
The mouse hepatoma HepA ascites tumor cells were maintained in ICR mice by weekly intraperitoneal transplantation into fresh ICR mice and were collected for transplantation under sterile conditions. Tumor xenografts were established in 5-to 7-week-old ICR mice (18-20 g) by injection of approximately 2 × 10 6 HepA cells in the right shoulder area. When the tumors were about 0.8 cm in diameter (about 7 days), the mice were used for biodistribution as described below. Tc-TMHHA) in a volume of 0.2 mL and activity of approximately 3.7 MBq. Groups of mice were sacrificed by decapitation at 5, 10, 15, 30, 60, 120 and 180 min after injection. The organs of interest (heart, muscle, lung, kidney, spleen, liver and tumor etc.) were dissected and weighed, as well as 100 μL blood were taken from carotid artery. The activity for each sample was determined by a γ counter. Distribution of the radioactivity in different tissues and organs was calculated and expressed as percentage of injection dose per gram (%ID/g).
Biodistribution in Tumor-
Conclusions
TMHEA and TMHHA, two kinds of novel thymidine derivative, have been prepared and successfully labeled with 99m Tc in a high labeling yield and good in vitro stability. Tc-NHT, which means limitless extension of the carbon chain is not always beneficial to improve the uptake ratios.
